v3.26.1
Business Combination (Tables)
 6 Months Ended
Jun. 30, 2026
Business Combination  
Summary of purchase consideration

​

​

​

​

​

(In thousands)

  ​ ​ ​

Purchase Consideration

Cash consideration payments to LymphaTech stockholders

​

$

7,230

Estimated fair value of contingent consideration

​

​

4,863

Total purchase consideration

​

$

12,093
Schedule of fair Value of assets acquired and liabilities assumed

​

​

​

​

​

​

​

(In thousands)

  ​ ​ ​

Estimated Fair Value

Assets

​

​

Current assets

​

​

Cash and cash equivalents

​

$

1,004

Accounts receivable, net

​

​

19

Total current assets

​

​

1,023

Non-current assets

​

​

Intangible assets

​

​

4,110

Goodwill(1)

​

​

8,491

Total non-current assets

​

​

12,601

Total assets acquired

​

$

13,624

Liabilities and stockholders' equity

​

​

​

Current liabilities

​

​

Accrued expenses and other current liabilities

​

$

180

Unearned revenue

​

​

313

Total current liabilities

​

​

493

Non-current liabilities

​

​

Deferred income taxes

​

​

1,038

Total long term liabilities

​

​

1,038

Total liabilities assumed

​

$

1,531

​

​

​

​

Net assets acquired

​

$

12,093

​

(1)Of the $8.5 million of goodwill from the acquisition, none is expected to be tax deductible. Goodwill is comprised of expected synergies for the combined operations and the assembled workforce acquired in the acquisition.
Schedule of estimated useful lives and preliminary fair values of intangible assets

​

​

​

​

​

​

(In thousands)

  ​ ​ ​

Estimated Fair Value(1)

​

Estimated Useful Life

Developed technology

​

$

3,200

​

10 years

Customer relationships

​

​

540

​

5 years

Tradename

​

​

370

​

10 years

Estimated fair value of intangible assets acquired

​

$

4,110

​

​

​

(1)The preliminary acquisition accounting, including the valuation of identifiable intangible assets, is subject to change during the measurement period.